Wire · opportunities
US FDA approves Abbott's longer-length Esprit for severe PAD
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 July 2026 · Fusion42 review
The US FDA has approved Abbott's longer-length Esprit BTK scaffold (76mm) for treating chronic limb-threatening ischaemia, designed to reduce procedural complexity by treating longer lesions with fewer devices. Most below-the-knee lesions in CLTI patients exceed 100mm, making the extended length clinically relevant for workflow efficiency.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're selling software or hardware into vascular labs, Abbott just removed a procedural friction point—treating longer lesions now takes one device instead of two. The labs that adopt Esprit Long Length will need faster imaging, better planning tools, or faster catheter handling to keep up.
◆ Coverage
1 source · 16 Jul 2026
◆ Related on Wire
◆ Topics